Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 19;15(2):2892-905.
doi: 10.3390/ijms15022892.

NTCP and beyond: opening the door to unveil hepatitis B virus entry

Koichi Watashi  1 , Stephan Urban  2 , Wenhui Li  3 , Takaji Wakita  4
Affiliations
Review

NTCP and beyond: opening the door to unveil hepatitis B virus entry

Koichi Watashi et al. Int J Mol Sci. .

Abstract

Chronic hepatitis B virus (HBV) infection, affecting approximately 240 million people worldwide, is a major public health problem that elevates the risk of developing liver cirrhosis and hepatocellular carcinoma. Given that current anti-HBV drugs are limited to interferon-based regimens and nucleos(t)ide analogs, the development of new anti-HBV agents is urgently needed. The viral entry process is generally an attractive target implicated in antiviral strategies. Using primary cells from humans and Tupaia belangeri, as well as HepaRG cells, important determinants of viral entry have been achieved. Recently, sodium taurocholate cotransporting polypeptide (NTCP) was identified as an HBV entry receptor and enabled the establishment of a susceptible cell line that can efficiently support HBV infection. This finding will allow a deeper understanding of the requirements for efficient HBV infection, including the elucidation of the molecular entry mechanism. In addition, pharmacological studies suggest that NTCP is able to serve as a therapeutic target. This article summarizes our current knowledge on the mechanisms of HBV entry and the role of NTCP in this process.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of the hepatitis B virus (HBV) lifecycle. Nucleos(t)ide analogs inhibit reverse transcription. Myrcludex-B, cyclosporin A and some NTCP inhibitors can inhibit the viral entry process by targeting NTCP.
See this image and copyright information in PMC

References

    1. Ott J.J., Stevens G.A., Groeger J., Wiersma S.T. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219. - PubMed
    1. Zoulim F., Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int. 2013;33:116–124. - PubMed
    1. Zoulim F., Perrillo R., Hepatitis B. Reflections on the current approach to antiviral therapy. J. Hepatol. 2008;48:S2–S19. - PubMed
    1. Marcellin P., Bonino F., Yurdaydin C., Hadziyannis S., Moucari R., Kapprell H.P., Rothe V., Popescu M., Brunetto M.R. Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol. Int. 2013;7:88–97. - PMC - PubMed
    1. Belloni L., Allweiss L., Guerrieri F., Pediconi N., Volz T., Pollicino T., Petersen J., Raimondo G., Dandri M., Levrero M. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 2012;122:529–537. - PMC - PubMed

Publication types

MeSH terms

Substances